Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 16/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18312222 | 0.78 | PI4KA (0.44) | DHFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2125192 | 0.77 | DHFR (1.00) | DHFR | |
| SCHEMBL31570707 | 0.73 | TUBB4A (0.42) | DHFREGFRTYMSPDGFRBKDR | |
| SCHEMBL1328569 | 0.68 | DHFR (0.47) | DHFREGFRTYMSPDGFRBKDR | |
| SCHEMBL18312022 | 0.68 | PI4KA (0.48) | EGFRPDGFRBKDRPI4KAPI4K2B | |
| SCHEMBL2124702 | 0.68 | PI4KA (0.48) | DHFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL8664052 | 0.68 | PI4KA (0.48) | DHFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17227469 | 0.68 | PI4KA (0.48) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28185600 | 0.68 | PI4KB (0.48) | EGFRKDRPI4KAPI4K2BPI4K2A | |
| SCHEMBL4746293 | 0.68 | MAP4K4 (0.50) | EGFRKDRPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014953-B1 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-6911446-B2 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | SUGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-6696482-B2 | QUINAZOLINE, NITROTHIAZOLE AND INDOLINONE BASED HYDROPHOBIC FORMULATIONS FOR ORAL ADMINISTRATION FOR TREATING CELL PROLIFERATION DISORDER IN A MAMMAL | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | TANG PENG C (US) | 2001-08-16 | — | — | US | disclosed |
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | SHENOY NARMADA (US) | 2001-08-09 | — | — | US | disclosed |
| US-6248771-B1 | MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR | SUGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6204267-B1 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | SUGEN, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-1014953-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | Sugen, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0981519-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | Sugen, Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050370-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998038984-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | ABCG2, SLC7A5, SLCO4C1 | DHFR 420/4885EGFR 3610/4885TYMS 911/4885 |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | RAF1, STK3, MKNK1 | DHFR 1842/4885EGFR 2016/4885TYMS 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.